Table 4 Antibiotic susceptibility profiles of NMEC and HFEC. Number of isolates (stated as percentages) in NMEC and HFEC were categorized as Sensitive (S), Intermediate (I) or Resistant (R) according to CLSI standards
From: Characterizing the pathotype of neonatal meningitis causing Escherichia coli (NMEC)
Antibiotic | NMEC | Â | Â | HFEC | Â | Â |
|---|---|---|---|---|---|---|
| Â | S | I | R | S | I | R |
Ampicillin | 50.94 | 3.773585 | 45.28 | 64.58 | 4.167 | 31.25 |
Cefazolin | 96.23 | 0 | 3.77 | 93.75 | 0 | 6.25 |
Cefepime | 96.23 | 0 | 3.77 | 100 | 0 | 0 |
Cefotaxime | 90.57 | 0 | 9.43 | 93.75 | 0 | 6.25 |
Cefoxitin | 90.57 | 0 | 9.43 | 95.83 | 2.08 | 2.08 |
Cefpodoxime | 90.57 | 0 | 9.43 | 9.16 | 0 | 8.33 |
Ceftazidime | 90.57 | 0 | 9.43 | 93.75 | 0 | 6.25 |
Ceftriaxone | 88.68 | 1 | 9.43 | 91.66 | 2.08 | 6.25 |
Cephalothin | 100 | 0 | 0 | 100 | 0 | 1 |
Ciprofloxacin | 100 | 0 | 0 | 100 | 0 | 0 |
Gentamicin | 100 | 0 | 0 | 100 | 0 | 0 |
Imipenem | 100 | 0 | 0 | 100 | 0 | 0 |
Meropenem | 100 | 0 | 0 | 100 | 0 | 0 |
Piperacillin/Tazobactam | 100 | 0 | 0 | 100 | 0 | 0 |
Ceftazidime/Clavulanic acid | 100 | 0 | 0 | 100 | 0 | 0 |
Amikacin | 100 | 0 | 0 | 100 | 0 | 0 |
Amoxicillin | 100 | 0 | 0 | 60.41 | 2.083 | 37.5 |
Chloramphenicol | 94.34 | 0 | 5.66 | 97.91 | 2.083 | 0 |
Sulfa/Trimethoprim | 81.13 | 0 | 18.86 | 93.75 | 0 | 6.25 |
Kanamycin | 86.79 | 2 | 9.433 | 100 | 0 | 0 |
Nalidixic acid | 96.23 | 0 | 3.773 | 81.25 | 0 | 18.75 |
Sulfisoxazole | 67.92 | 3 | 14 | 68.75 | 16.66 | 14.58 |
Tetracycline | 81.13 | 0 | 10 | 91.66 | 0 | 8.33 |